Metabolic efficacy
Evaluate candidate activity in protocol-defined type 2 diabetes study formats.
METABOLIC DISEASE MODEL
Type 2 Diabetes Rat Models
Documented type 2 diabetes platforms include STZ/high-fat-diet-induced rat studies and ZDF rat models for metabolic-disease pharmacology.
Model format, baseline metabolic phenotype, treatment schedule, sampling plan, and glycemic or exposure endpoints are confirmed during technical review.
MODEL OVERVIEW
Type 2 diabetes models selected around disease context and candidate mechanism.
STZ/HFD and ZDF rat platforms provide complementary type 2 diabetes contexts that can be aligned to the candidate modality, treatment window, metabolic readouts, and required PK/PD or biomarker package.
Therapeutic areaType 2 diabetes
SpeciesRat
Model formatSTZ/HFD, ZDF
Typical useEfficacy, Biomarkers, PK/PD
TYPICAL APPLICATIONS
What this model can support.
Dose and schedule comparison
Compare dosing levels, routes, schedules, and treatment windows against predefined metabolic objectives.
Biomarker studies
Integrate protocol-defined glycemic and metabolic biomarkers with the efficacy program.
PK/PD integration
Link systemic exposure to pharmacodynamic or efficacy measurements when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Glycemic phenotype
Protocol-defined glucose-control and disease-state measurements.
Metabolic biomarkers
Fit-for-purpose metabolic biomarker panels selected for the program.
Exposure
Plasma or selected tissue exposure when PK is incorporated.
Tissue outputs
Protocol-defined tissue collection for pathology or downstream analysis.
Exact induction conditions, ZDF cohort characteristics, study-entry criteria, endpoints, and timeline are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- STZ/HFD or ZDF study format
- Baseline metabolic phenotype and entry criteria
- Dose route, schedule, and formulation
- Treatment duration
- Glycemic and metabolic endpoints
- PK/PD and tissue requirements
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a Type 2 Diabetes study.Required fields are marked with an asterisk(*).